Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality

• US 7,179,612 B2
• Filed: 06/08/2001
• Issued: 02/20/2007
• Est. Priority Date: 06/09/2000
• Status: Expired due to Term

• Current Assignee: Biomerieux Incorporated (Compagnie Merieux Alliance SAS)
• Original Assignee: Biomerieux Incorporated (Compagnie Merieux Alliance SAS)
• Inventors: Fischer, Timothy J., Downey, Colin, Tejidor, Liliana, Toh, Cheng-Hock, Nesheim, Mike, Samis, John A., Walker, John B.
• Primary Examiner(s): Chan; Christina
• Assistant Examiner(s): HUYNH, PHUONG N
• Application Number:
  US10/019,087
• Publication Number:
  US 20020193949A1
• Time in Patent Office: 2,083 Days
• Field of Search: 436/69, 436/71, 436/34, 436/164, 436/517, 436/536, 436/805, 436/80, 435/11
• US Class Current: 435/11
• CPC Class Codes: G01N 2800/044 Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/86 involving blood coagulating time or factors, or their receptors
• CPC Class Codes: G01N 33/92 involving lipids, e.g. cholesterol , lipoproteins, or their receptors steroid hormones G01N33/743

Abstract

A method for diagnosing a condition of a patient involves the steps of (a) adding one or more reagents to a test sample from a patient, the test samples comprising at least part of a blood sample from the patient, in order to cause formation of a complex comprising at least one acute phase protein and at least one human lipoprotein, while causing substantially no fiber polymerization; (b) measuring the formation of the complex over time so as to derive a time-dependent measurement profile, and (c) determining a slope and/or total change in the time-dependent measurement profile, so as to diagnose a condition of the patient. A greater formation of the complex is correlated to increased probability of death of the patient.

Claims

1. A method for testing the effectiveness of a therapeutic for treatment of hemostatic dysfunction, comprising the steps of (a) providing a test sample from a patient with hemostatic dysfunction, (b) adding a divalent metal cation reagent to the test sample wherein the reagent does not cause fibrin formation, (c) measuring the formation of a complex comprising C reactive protein (CRP) and at least one human lipoprotein selected from the group consisting of very low density lipoprotein (VLDL) and intermediate density lipoprotein (IDL), (d) administering a therapeutic to said patient, (e) repeating the steps (a) through (d) at a later time, wherein a decrease in said complex formation at said later time is indicative of the efficacy of said therapeutic for treatment of hemostatic dysfunction.

2. The method of claim 1, wherein the hemostatic dysfunction is disseminated intravascular coagulation (DIC).

3. The method of claim 1, wherein the at least one human lipoprotein is a very low density lipoprotein (VLDL).

4. The method of claim 1, wherein the at least one human lipoprotein is an intermediate density lipoprotein (DL).

5. The method of claim 1, wherein the at least one human lipoprotein further comprises a chylomicron.